Jubilant Ingrevia Ltd Q1 FY2027 Concall Summary

Key Takeaways

• Strong Q1, guidance held: Revenue hit a 15-quarter high, with EBITDA of ₹209 crore putting the company on track for its ₹750–800 crore full-year target. Management declined to upgrade the number despite the beat, citing acetyl volatility.
• Nutrition & Health is the standout: Revenue jumped 36% YoY and EBITDA hit a 3-year high, powered by firm B3 pricing and a fast-ramping niacinamide plant. The segment is now a material profit driver.
• CDMO is gaining commercial traction: The big innovator contract began contributing positive EBITDA, and the pipeline added 5 new early-stage molecules after a U.S. and Europe roadshow. Full-year EBITDA protection on the large contract remains in place.
• Acetyls delivered a sharp rebound: Revenue rose 38% YoY and EBITDA 240% YoY on strong demand and price pass-throughs, but management flagged this as the swing factor that keeps full-year guidance cautious.
• What to watch next quarter: Whether the large CDMO customer provides volume visibility for H2, the pace of niacinamide plant ramp-up toward 70% utilization, and the trajectory of B3 pricing as Q2 bookings roll off.

Segment Performance

• Sequential growth drivers: Fine chemicals, CDMO and nutrition all posted sequential volume and portfolio expansion. The niacinamide plant is filling capacity fast. Acetyls/chemical intermediates performed well in Q1 and the trend is continuing into the current quarter on the back of recent oil and raw material price escalations.
• Specialty Chemicals Q4-to-Q1 dynamics: Q4 is typically a heavy quarter due to year-end effects; some orders can shift by one quarter. CDMO grew on the big order but did not serve full volumes in Q1 because the customer asked to defer some to Q2 due to raw material price escalations. Pyridine volumes were stable but pricing pressure partially offset growth. Fine Chemicals remained strong though Q4 is its seasonal peak.
• Nutrition inventory risk contained: Last quarter's flagged risk of high raw material inventory with crashing finished good prices did not fully materialize. The company was careful building stock; finished goods prices came down only modestly from the peak, and due to the war restarting, prices have started moving up again in certain segments. Inventory carryover impact from Q1 to Q2 is expected to be very minimal.
• Power, fuel and other expenses: Power and fuel costs rose on higher volumes and increased LSHS/natural gas costs from the Gulf crisis. Other expenses rose mainly on logistics costs, both domestic and international, which were successfully passed on to customers and reflected in higher pricing.

Deepak Jain: "Now in some quarters, some business fires and some business does not fire because of specific factors, which are outside of control. But as a portfolio, I think that is why we feel more confident in giving the guidance on the overall business."

CDMO: Pipeline, Contract Economics & Visibility

• Big contract EBITDA protection confirmed: The plant ran smoothly with supplies starting in March and continuing through Q1. Full volumes were not served because raw material prices escalated due to the war and the innovator asked for a temporary pause until pricing came down. Positive EBITDA was reflected in Q1 numbers. Management reiterated that in the unforeseen circumstance of no volume, full protection exists that will more than cover whatever EBITDA expectations were communicated to the markets.
• Pipeline dynamism: The funnel composition changes every month, not just every quarter. Five new molecules were added, most from pharma or personal care and all early-stage, so peak potential is difficult to estimate. At least 10 new opportunities from U.S. customer meetings are not yet reflected in the last quarter's numbers.
• Confirmed molecules revenue contribution: Based on earlier calculations and assuming full revenue from the big contract, confirmed molecules were supposed to contribute at least 25% of the combined Specialty and Nutrition portfolio. Depending on where big contract volumes land, there could be some revenue adjustment, but in EBITDA terms the company expects to maintain what was committed.
• Volume visibility gap: The large CDMO customer has not given a firm timeline for providing full volume visibility. To plan for Q3, the company will need some clarity within the next month or so. Volumes in the current quarter will be more than in the previous quarter.
• Molecule ramp-up: At least a few molecules are expected to see higher volumes in their second year versus the first. Most Western customers give volume indications by August/September and confirmation by October for the following year.
• Peak revenue disclosure declined: Management did not provide an updated peak revenue number for the CDMO order book, saying most of the 5 new molecules are early-stage and the ₹1,500 crore figure has not been updated.

Deepak Jain: "In the unforeseen circumstances of they not giving us any volume, we have full protection, which will more than cover for whatever EBITDA expectations we have communicated to the markets."

Nutrition & Health: Pricing, Ramp-Up & Mitigation

• B3 volumes and pricing trajectory: Overall B3 volumes increased, with the high-value segment (niacin and niacinamide cosmetic grade from the new plant) also rising. Historically, when B3 prices move up they stay up for at least 2–3 quarters. Prices were up in Q1 with spillover into Q2; based on historical trends, prices may start to come down by the end of Q2.
• Mitigation strategy: The company is increasing the mix of high value-add products (food grade, pharma grade, cosmetic grade) and pursuing continuous cost improvement. Management stated that even if pricing comes down, the richer mix should limit the impact.
• Niacinamide plant ramp-up: Utilization is expected to move from 50% to 70% plus by the end of this year. The plant is filling capacity very fast.
• Q2 comfort: A lot of Q2 booking is already done, so the quarter feels comfortable. If pricing comes down, the impact would be felt in Q3 pricing, with mitigation actions helping protect margins.

Deepak Jain: "The good thing for us is because the relative mix of high value-add products on the food grade, pharma grade and cosmetic grade is increasing, the pricing, even if it comes down, hopefully, it should not impact us significantly."

Pyridine & Derivatives: Volume Strength, Pricing Divergence

• Market position and utilization: The company is the world leader in pyridine and derivatives, with the plant running at 95%+ utilization. Momentum on the volume side is strong.
• Pricing divergence by derivative: Commoditized variants, including the building block, face pricing pressure due to overcapacity in China. The focus is on pyridine downstream, more advanced derivatives, and the picoline part where pricing is holding up.
• Captive consumption rising: The percentage of captive usage is increasing year-on-year, especially for picoline (beta-picoline goes into B3 production). With B3 volumes growing substantially, a lot of beta-picoline is being consumed internally. The relative share of captive consumption across the whole pyridine and picoline family is increasing and is significant, though management declined to disclose the specific ratio.

Guidance Philosophy & The Acetyl Swing Factor

• Full-year guidance maintained at ₹750–800 crore: Despite ₹209 crore of Q1 EBITDA and commentary pointing to sequential improvement, management declined to upgrade. The logic: roughly ₹200 crore EBITDA per quarter in H1 would put the first half at around ₹400 crore plus, keeping the full-year number within reach.
• The acetyl wildcard: Acetyls are doing well and continue to do well in the current quarter. On the back of some orders booked with customers, management is hopeful that if they materialize in time, the company can beat the target. However, given the volatility in the acetyl segment, there is risk the market could go down again in Q3/Q4, so overall guidance is maintained at the discussed levels.
• Portfolio logic: Over the last three years, the company has grown from ~₹100 crore EBITDA per quarter to ₹209 crore. In any given quarter, some businesses fire and some do not due to factors outside management's control. The portfolio approach is what gives management confidence in the overall guidance.

Deepak Jain: "We are hopeful that if they materialize in time, we can hopefully beat the target that we have set for ourselves... But given the volatility which exists in the market, particularly on the Acetyl segment, we never know what happens in Q4, right?"

Strategic Initiatives & Integration

• Remidex Pharma integration complete: The integration has been successfully completed, with encouraging traction from Tier 1 human nutrition customers.
• New R&D facility: A dedicated R&D and clean room facility is being built at Greater Noida for semiconductors and electronics.
• New multipurpose plant (MPP): Remains on track for commissioning by the end of the current calendar year (end of 2026), further strengthening the CDMO and Fine Chemicals growth roadmap.
• Lean savings target: The company is targeting ₹100 crore of lean savings in FY27.
• M&A pipeline: Management is actively evaluating new growth opportunities across high-potential segments such as electronics, semiconductors, cosmetics and nutrition.
• Customer and safety milestones: Over 20 customer quality and EHS audits were successfully cleared during the quarter. The company maintained an exemplary safety record and earned multiple recognitions, including Great Place to Work certification and British Safety Council International Safety Awards.

Guidance & Commitments

Key Metrics